Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Breast Cancer Organoids
- Interventions
- Drug: PattozumabDrug: Ear particles
- Registration Number
- NCT03925233
- Lead Sponsor
- Xijing Hospital
- Brief Summary
Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 300
Patients with breast cancer and the largest tumor diameter ≥ 3cm No previous chemotherapy regimen age 18-65 years old Can obtain the tumor tissue specimens required for culture Heart, liver, kidney and bone marrow hematopoietic function is good Know and sign the informed consent form
Pregnant or lactating women Also suffering from other cancer patients There are serious uncontrolled medical diseases or acute infections Those who are known to be allergic to this study drug or a variety of previous drugs The patient cannot understand the purpose of the study or disagree with the requirements of the study.
Other investigators believe that patients who are not suitable for this study group
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description HER2+ Breast Cancer Ear particles - ER+ Breast Cancer Trastuzumab - Triple Negative Breast Cancer Doxorubicin Hydrochloride - Triple Negative Breast Cancer Epirubicin hydrochloride - HER2+ Breast Cancer Carboplatin - HER2+ Breast Cancer Bevacizumab - HER2+ Breast Cancer Pattozumab - HER2+ Breast Cancer Epirubicin hydrochloride - HER2+ Breast Cancer Gemcitabine - HER2+ Breast Cancer Doxorubicin Hydrochloride - HER2+ Breast Cancer Tamoxifen citrate - HER2+ Breast Cancer Eribulin mesylate - HER2+ Breast Cancer Toremifene citrate - ER+ Breast Cancer Doxorubicin Hydrochloride - ER+ Breast Cancer Tamoxifen citrate - ER+ Breast Cancer Carboplatin - Triple Negative Breast Cancer Cisplatin - HER2+ Breast Cancer Vinorelbine tartrate - HER2+ Breast Cancer Fluorouracil - HER2+ Breast Cancer Recombinant Human Endostatin - HER2+ Breast Cancer Methotrexate - ER+ Breast Cancer Pirarubicin hydrochloride - ER+ Breast Cancer Ear particles - HER2+ Breast Cancer Pirarubicin hydrochloride - HER2+ Breast Cancer Apatinib mesylate - HER2+ Breast Cancer Aidi Injection - ER+ Breast Cancer Epirubicin hydrochloride - ER+ Breast Cancer Toremifene citrate - ER+ Breast Cancer Vinorelbine tartrate - ER+ Breast Cancer Apatinib mesylate - ER+ Breast Cancer Fulvestrant - ER+ Breast Cancer Pattozumab - Triple Negative Breast Cancer Ear particles - Triple Negative Breast Cancer Tamoxifen citrate - Triple Negative Breast Cancer Vinorelbine tartrate - Triple Negative Breast Cancer Apatinib mesylate - Triple Negative Breast Cancer Pirarubicin hydrochloride - Triple Negative Breast Cancer Ixabepilone - Triple Negative Breast Cancer Methotrexate - Triple Negative Breast Cancer Eribulin mesylate - Triple Negative Breast Cancer Toremifene citrate - Triple Negative Breast Cancer Anastrozole - Triple Negative Breast Cancer Pattozumab - Triple Negative Breast Cancer Capecitabine - Triple Negative Breast Cancer Cyclophosphamide - ER+ Breast Cancer Aidi Injection - Triple Negative Breast Cancer Aidi Injection - HER2+ Breast Cancer Cisplatin - ER+ Breast Cancer Capecitabine - Triple Negative Breast Cancer Fulvestrant - HER2+ Breast Cancer Ixabepilone - HER2+ Breast Cancer Trastuzumab - HER2+ Breast Cancer Paclitaxel - HER2+ Breast Cancer Exemestane - HER2+ Breast Cancer Anastrozole - HER2+ Breast Cancer Letrozole - HER2+ Breast Cancer Olaparib - HER2+ Breast Cancer Fulvestrant - ER+ Breast Cancer Fluorouracil - HER2+ Breast Cancer Capecitabine - HER2+ Breast Cancer Cyclophosphamide - ER+ Breast Cancer Paclitaxel - ER+ Breast Cancer Gemcitabine - ER+ Breast Cancer Cisplatin - ER+ Breast Cancer Recombinant Human Endostatin - ER+ Breast Cancer Pyrrolidine - ER+ Breast Cancer Ixabepilone - ER+ Breast Cancer Methotrexate - ER+ Breast Cancer Eribulin mesylate - ER+ Breast Cancer Anastrozole - ER+ Breast Cancer Letrozole - ER+ Breast Cancer Exemestane - ER+ Breast Cancer Olaparib - ER+ Breast Cancer Bevacizumab - ER+ Breast Cancer Cyclophosphamide - Triple Negative Breast Cancer Trastuzumab - Triple Negative Breast Cancer Fluorouracil - Triple Negative Breast Cancer Paclitaxel - Triple Negative Breast Cancer Gemcitabine - Triple Negative Breast Cancer Recombinant Human Endostatin - Triple Negative Breast Cancer Carboplatin - Triple Negative Breast Cancer Olaparib - Triple Negative Breast Cancer Letrozole - Triple Negative Breast Cancer Exemestane - Triple Negative Breast Cancer Bevacizumab - HER2+ Breast Cancer Pyrrolidine - Triple Negative Breast Cancer Pyrrolidine -
- Primary Outcome Measures
Name Time Method Detection of cell viability 8 weeks before neoadjuvant chemotherapy 1. The organ-like organ was assayed for cell viability using CellTiter Glo 3D reagent, and the curve was used to obtain a half-inhibitory concentration range. The dose was adjusted according to the half-inhibition concentration range to obtain an accurate half-inhibitory concentration.
- Secondary Outcome Measures
Name Time Method Detection of in vitro model drug sensitivity 8 weeks before neoadjuvant chemotherapy 2. In vitro model drug sensitivity: sensitive and insensitive
Clinical efficacy assessment according to RECIST criteria 8 weeks before neoadjuvant chemotherapy Clinical efficacy evaluation according to RECIST criteria: imaging ultrasonography, histological pathology.
Trial Locations
- Locations (1)
JingSu
🇨🇳Xi'an, Shaanxi, China